This content is from: Premium
After a Tough 2021, RTW is Still Bullish
One of the hottest biopharma and life sciences funds in recent years is confident that it can rebound from last year’s setback.
The sharp selloff in fledgling biopharma and life sciences stocks in the past year or so has not spared RTW Investments. The fund was down more than 9 percent in 2021 and lost another 17.6 percent in January of this year.Even so, its recent setbacks were not as painful as
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.